Short answer
Trevi Therapeutics, Inc. (TRVI) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$18M
- −44.7% YoY · −34.9% QoQ
- EPS (diluted)
- −$0.12
- −33.3% YoY · −33.3% QoQ
Source: XBRL data from the Trevi Therapeutics, Inc. (TRVI) Q2 2026 10-Q on SEC EDGAR. USD.
Trevi Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0; no product sales, versus $0 in Q2 2025
- Net loss $17.8M vs $12.3M YoY; operating loss $20.5M vs $13.7M
- R&D highest-spending program area, $15.2M vs $9.4M, driven by OCEAN-1 and LAKE trials
- Cash, equivalents and marketable securities $318.9M at June 30, 2026; operating cash use $34.1M vs $23.6M
- April offering generated $162.3M net proceeds; management expects funding for at least 12 months, but substantial additional funding remains necessary
Risk Factors
- New disclosure risk: market value above $700.0 million eliminates smaller-reporting-company accommodations beginning fiscal 2027
- Regulatory disclosure risk: continued scaled disclosures through fiscal 2026 may reduce investor comparability
- Competitive risk: taplucainium remains in RCC development while Haduvio lacks approval
- Market risk: potential fibrosis therapies could reduce demand for chronic-cough treatment in IPF and ILD
- Competitive resource risk: larger rivals possess greater clinical, manufacturing, and commercialization capabilities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Trevi Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.